

CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 5, 2004
Date


Shelley P.M. Fussey

1617

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING
ANTIBODIES TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A non-final Official Action on the merits has been received in the present application. However, this Supplemental Information Disclosure Statement is being filed prior to the mailing of a final Official Action, notice of allowance or an Action that closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a counterpart foreign application. The listed documents were identified during research conducted by legal representatives of the licensee of the present application in connection with the licensee's Opposition against a European patent to another. The research was initiated on about July 20, 2004, and was completed on August 20, 2004, and the present statement is being filed within three months of the initiation of the research.

No fees are due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this Supplemental Information Disclosure Statement, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: October 5, 2004

Form PTO-1449 (modified)

Atty. Docket No.

4001.002282

Serial No.

09/351,862

List of Patents and Publications for Applicant's

Applicant

Thorpe and Ran

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

July 12, 1999

Group:

1617

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Pages 1-2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No


Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C93	Auerbach, "Vascular Endothelial Cell Differentiation: Organ-Specificity and Selective Affinities as the Basis for Developing Anti-Cancer Strategies," <i>Int. J. Radiat. Biol.</i> , 60(1/2):1-10, 1991.
	C94	Brown <i>et al.</i> , "Leaky Vessels, Fibrin Deposition, and Fibrosis: A Sequence of Events Common to Solid Tumors and to Many Types of Disease," <i>Am. Rev. Respir. Dis.</i> , 140:1104-1107, 1989.
	C95	Clauss <i>et al.</i> , "Vascular Permeability Factor: A Tumor-Derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration," <i>J. Exp. Med.</i> , 172:1535-1545, 1990.
	C96	Denekamp, "Vasculature as a Target for Tumour Therapy," <i>Prog. Appl. Microcirc.</i> , 4:28-38, 1984.
	C97	Dvorak <i>et al.</i> , "Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation," <i>Ann. N.Y. Acad. Sci.</i> , 667:101-111, 1992.
	C98	Dvorak, "Leaky Tumor Vessels: Consequences for Tumor Stroma Generation and for Solid Tumor Therapy," <i>Progress in Clinical and Bioological Research</i> , 354a: 317-330, 1990.
	C99	Dvorak, "Tumors: Wounds That Do Not Heal," <i>New Eng. J. Med.</i> , 315(26):1650-1659, 1986.
	C100	Dvorak <i>et al.</i> , "Regulation of Extravascular Coagulation by Microvascular Permeability," <i>Science</i> , 227:1059-1061, 1985.
	C101	Dvorak <i>et al.</i> , "Fibrin as a Component of the Tumor Stroma: Origins and Biological Significance," <i>Cancer Metastasis Reviews</i> , 2:41-73, 1983.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
 4001.002282

Serial No.
 09/351,862

Applicant
 Thorpe and Ran

Filing Date:
 July 12, 1999

Group:
 1617

U.S. Patent Documents
See Page

Foreign Patent Documents
See Page

Other Art
See Pages 1-2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C102	Folkman and Ingber, "Inhibition of Angiogenesis," <i>Seminars in Cancer Biology</i> , 3:89-96, 1992.
	C103	Folkman and Shing, "Angiogenesis," <i>J. Biol. Chem.</i> , 267(16):10931-10934, 1992.
	C104	Folkman <i>et al.</i> , "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," <i>Nature</i> , 339:58-61, 1989.
	C105	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?," <i>J. Natl. Cancer Inst.</i> , 82(1):4-6, 1990.
	C106	Folkman and Klagsbrun, "Angiogenic Factors," <i>Science</i> , 235:442-447, 1987.
	C107	Greenblatt and Shubi, "Tumor Angiogenesis: Transfilter Diffusion Studies in the Hamster by the Transparent Chamber Technique," <i>J. Natl. Cancer Inst.</i> , 41:111-124, 1968.
	C108	Jain, "Haemodynamic and Transport Barriers to the Treatment of Solid Tumours," <i>Int. J. Radiat. Biol.</i> , 60(1/2):85-100, 1991.
	C109	Kerbel, "Inhibition of Tumor Angiogenesis as a Strategy to Circumvent Acquired Resistance to Anti-Cancer Therapeutic Agents," <i>BioEssays</i> , 13(1):31-36, 1991.
	C110	Weidner, "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma," <i>New. Eng. J. Med.</i> , 324(1):1-7, 1991.

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.